NeurAxis (NRXS) Company Overview

CARMEL, Ind., Jan. 21, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), with a prominent insurer, with approximately 5.1 million members across 13 states.

CARMEL, Ind., Jan. 21, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), with Molina Healthcare. Molina, with over 40 years in operation, has approximately 5.1 million members across 13 states.

CARMEL, Ind., Jan. 13, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced that CEO Brian Carrico has published a letter to shareholders highlighting the Company's achievements in 2024 and vision for 2025.

NeurAxis, Inc (NYSE:NRXS ) Q3 2024 Results Conference Call November 12, 2024 9:00 AM ET Company Participants Ben Shamsian - Investor Relations Brian Carrico - Chief Executive Officer Tim Henrichs - Chief Financial Officer Operator Good day, and thank you for standing by. Welcome to the NeurAxis's Third Quarter 2024 Financial Results Conference Call.

NRXS reports strong third-quarter results with rising revenues, reduced losses and expanded insurance coverage, driving its stock to outperform the market.

Conference call will be held today, Tuesday, November 12 at 9:00 am ET Conference call will be held today, Tuesday, November 12 at 9:00 am ET

Discover why Zacks rates NeurAxis as "Neutral", being the first on Wall Street to initiate coverage on the stock. Explore NRXS' promising growth prospects and financial health amid market challenges.

CARMEL, Ind., Sept. 19, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will participate in a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2024 Investor Conference, taking place virtually on Tuesday, October 1, 2024.

CARMEL, Ind., Aug. 13, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), for Blue Cross Blue Shield (BCBS) of Vermont Medical Members, effective 10/1/2024. This medical policy will bring our national total coverage for PENFS to roughly 23 million, with more decisions from major payers still pending.